Now I have sufficient information to write a comprehensive earnings preview.Now I have all the information needed. Let me write the comprehensive earnings preview.# Alexandria Real Estate Equities (ARE) — Q2 2026 Earnings Preview Report Date: Monday, August 3, 2026 (after market close)
Alexandria — the dominant life-science/lab-space REIT and owner of "Megacampus" clusters in Boston, San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and NYC — reports Q2 2026 results tomorrow after the close. Sentiment heading in is relatively neutral, with support from cheap valuation, a decent dividend, and a long-term attractive asset footprint, though this is offset by continued occupancy headwinds, with the Street not expecting occupancy to reach a trough for years to come.
The stock has been volatile in 2026 — it ran from the high-$40s in January to nearly $60 in late January, cratered to the low-$40s after the disappointing Q1 print (April 28), and has since recovered into the low-$50s heading into this report (~$51.47 as of July 31).
Alexandria is executing a multi-year "path forward" (laid out at its December 2025 Investor Day) built around six pillars: protect the balance sheet, cut capital spend, complete a large noncore disposition program, rebuild occupancy/NOI, cut G&A, and preserve optionality on buybacks. Q1 2026 was a rough proof point of that reset, and Q2 is the quarter management explicitly flagged as another pressure point before an expected second-half recovery.
Q1 occupancy fell to 87.7%, down 320 basis points from the prior quarter, primarily driven by the 657,000 square feet of key known lease expirations, which went vacant during the quarter. Management was explicit that Q2 would see further pressure: "We have an additional 747,000 square feet of key lease expirations expected to go vacant in 2026, with approximately 45% of that expected to expire in the second quarter, which should put pressure on occupancy for 2Q '26." Independent estimates echo this: the Zacks model calls for same-store revenue down 9.3% and same-store NOI down 18% in the quarter.
The bull case rests on a large backlog of already-signed-but-undelivered leases: "For the second half of '26, we expect occupancy to benefit from the 1.1 million square feet of vacant space that has been leased and is expected to deliver in September on a weighted average basis." That space carries roughly $68 million of annual rental revenue once delivered — investors should look for commentary confirming this delivery timeline is intact.
Q1 leasing volume was weak at 647,000 sq ft, and notably "this is maybe the first quarter in the history of the company that I can remember where we didn't sign a single public biotech lease." Management flagged a rebound: "Looking ahead to the second quarter, we do expect an uptick in total leasing volume of around 900,000 square feet, given the early activity to date." Whether ARE hits that level — and whether public biotech tenants re-emerge — will be a key scorecard item. CFO Marc Binda was careful to caveat this wasn't formal guidance: "Number one, it's not guidance. It's just an indication based on activity and transaction work."
Q1 saw renewal/re-leasing spreads fall 15.0% (GAAP) / 15.8% (cash), though "free rent and rental rate changes on renewed and re-leased space were under pressure in 1Q '26, which reflects the market realities and includes a 48,000 square foot lease at 40 Arsenal Watertown for a 12-year term, which was a significant contributor to the rental rate reduction." Full-year guidance for rate changes was cut further at Q1 (to -9% to -1% GAAP, -15% to -7% cash) versus original guidance, partly due to "a 48,000 square foot long-term lease completed during 1Q '26 in Watertown to an entertainment studio user and an 81,000 square foot lease completed in April with an exciting growth stage life science company to backfill a struggling tenant located in Torrey Pines." Watch whether Q2 spreads stabilize or deteriorate further.
ARE's 2026 plan calls for a $2.9 billion midpoint of dispositions/partial-interest sales, with the weighted-average completion date pushed back to August 2026 (a month later than original Investor Day guidance). As of the Q1 print, "our team is making good progress with about 80% of the $2.9 billion midpoint for dispositions and sales of partial interest pending or identified and in process." Management also signaled a strategic pivot toward joint ventures for core assets given renewed institutional appetite: "we believe there is strong institutional interest for our core assets at a reasonable cost of capital... we believe that joint ventures for some of our core assets could be a significant component of our capital plan." Investors should look for an updated disposition tally and mix (core/noncore/land/JV) — this directly funds the construction pipeline and delevering path.
Leverage ticked up to 6.8x net debt/EBITDA (quarter-annualized) in Q1 due to seasonally lower EBITDA, but guidance still targets 5.6x–6.2x by 4Q26. ARE has "tremendous liquidity of $4.2 billion and the longest average remaining debt maturity among all S&P 500 REITs of 10 years." In February 2026 the company executed debt tender offers, repurchasing $1.33 billion of bonds at a discount and booking a $366 million gain. More recently (July 9, 2026), ARE lined up a new $5 billion unsecured revolving credit facility with a $1 billion accordion, locking in lender commitments and pricing through the early 2030s — a proactive liquidity move investors should note held up during the reset period.
Management flagged that its reserve for tenant wind-downs/failures has crept higher: "we had identified something around $23 million [at Investor Day]. That number has crept up in terms of a reserve for wind downs or tenant failure. That number today is somewhere in that $25 million to $30 million range." Any further upward revision here would be a negative read on private/public biotech tenant stress.
Beyond the current quarter, ARE flagged that 2027 already has 1.5 million sq ft / ~$97 million of annual rental revenue of lease expirations expected to see downtime, and this number increased sequentially due to one large early tenant departure at the Waltham Megacampus. Commentary on progress leasing into this bucket (management noted early discussions covering roughly a third of it) will shape how investors think about the shape of the recovery beyond 2026.
Management's framing of the operating environment — reliant on NIH funding, FDA leadership stability, and biotech capital-markets access — remains a swing factor for demand, particularly from public biotech tenants (24% of ARR), which signed zero leases in Q1. Recent positives cited by the company include a court/administration reversal of the NIH indirect-cost cap and continued bipartisan NIH funding support; negatives include FDA leadership turnover and continued judicious/constrained biotech capital markets.
This is a "show-me" quarter for a REIT mid-transition: near-term fundamentals (occupancy, same-property NOI, rental spreads) are expected to look ugly, largely as pre-telegraphed by management, while the more important signals for the stock are forward-looking — the pace of disposition execution, whether the leasing pipeline (including a pivot toward advanced-technology tenants at several development sites) is translating into signed square footage, and whether the balance sheet actions (bond tender, new $5B credit facility) keep funding costs and leverage under control while the portfolio stabilizes. With Street sentiment already neutral-to-cautious and a "Hold" consensus rating, the stock's reaction is likely to hinge less on the magnitude of the expected Q2 FFO decline and more on management's tone regarding the second-half occupancy inflection and disposition completion timeline.